NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

NCT03638765

Study Contact
Name: Marnix L Bosch, PhD
Phone Number: 2404979022
Email: [e-mail]

Study Start (Estimated)
2018-11
Primary Completion (Estimated)
2019-12
Study Completion (Estimated)
2020-12
Enrollment (Estimated)
24
Study Type
Interventional
Phase 1

The study will use an Ommaya reservoir that drains into brain metastases to deliver activated, autolous dendritic cells to the tumor lesion, for patients who are 18 - 75 years old who have brain metastases from either lung cancer or breast cancer. The primary objective of the study is to evaluate the safety and feasibility of administering DCVax-Direct to patients with metastatic tumors in the brain. The secondary objectives are to determine tumor response, the rate of intracranial recurrence (IR), the rate of neurologic deaths, decline in neuro-cognitive functioning and overall survival. Approximately 10 patients with injectable metastatic brain tumors will be enrolled initially in a dose escalation scheme, with the expectation to enroll a total of 24 patients.

So when you stated this:

As far as Direct, that is just silly. NWBO has no manufacturing. And no doc is going to risk this type agent in the brain. — Exwannabe

You were wrong.